Lyndra Therapeutics is developing an orally administered dosage form designed to deliver sustained, steady-state release of one or more drugs for up to a week or longer while temporarily residing in the stomach. The foundation invested in the company to support the development and application of this new drug delivery technology for global health conditions that affect patients in low income countries.